Teprotumumab

Caroline Y. Yu; Jamie A. Keen; Erin M. Shriver

doi:10.1016/j.yaoo.2022.03.008

Back

Journal article

Peer reviewed

Teprotumumab

Caroline Y. Yu, Jamie A. Keen and Erin M. Shriver

Advances in ophthalmology and optometry, Vol.7(1), pp.383-400

08/2022

DOI: 10.1016/j.yaoo.2022.03.008

View Online

Abstract

Thyroid eye disease (TED) is an uncommon orbital inflammatory disease that can lead to disfigurement and permanent vision loss. Traditional therapies such as glucocorticoids and orbital radiation primarily were used to treat inflammation during the active phase of the disease. Teprotumumab, the first Food and Drug Administration-approved medication for TED, targets the insulin-like growth factor-1 receptor and has been shown to decrease proptosis, diplopia, and clinical activity score. In this review, the pathophysiology and treatment landscape of TED are summarized, and the mechanism, clinical data, and associated adverse events of teprotumumab are described in detail.

Dysthyroid optic neuropathy

Graves’ ophthalmopathy

Oculoplastics

Orbital inflammation

Strabismus

Teprotumumab

Thyroid eye disease

Details

Title: Subtitle: Teprotumumab
Creators: Caroline Y. Yu - Visual Sciences
Jamie A. Keen
Erin M. Shriver
Resource Type: Journal article
Publication Details: Advances in ophthalmology and optometry, Vol.7(1), pp.383-400
Publisher: Elsevier Inc
DOI: 10.1016/j.yaoo.2022.03.008
ISSN: 2452-1760
eISSN: 2452-1760
Language: English
Date published: 08/2022
Academic Unit: Otolaryngology; Ophthalmology and Visual Sciences
Record Identifier: 9984286060302771

Metrics

7 Record Views